Skip to main content
logo
Barinthus Biotherapeutics plc (BRNS)
Sep 9, 2026 - BRNS was delisted (reason: merged with CLYD)
0.7401
0.00 (0.00%)
Inactive · Last trade price on Sep 8, 2026

Barinthus Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--14.970.844.70.27
Revenue Growth
--1766.46%-98.21%16580.22%-94.44%
Gross Profit
8.59-0.1313.29-1.212.35-20.1
Operating Income
-32.13-58.07-45.65-80.4-2.87-41.22
Net Income
-41.77-66.43-61.07-73.355.34-50.87
Earnings Per Share
-1.02-1.64-1.55-1.910.14-1.96
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
59.370.46110.66142.09194.39214.05
Total Debt
10.311.2812.0112.988.777.22
Net Cash (Debt)
4959.1898.66129.11185.61206.83
Net Cash Growth
-34.02%-40.02%-23.59%-30.44%-10.26%-
Net Cash Per Share
1.201.462.513.364.867.99

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-26.43-47.98-28.94-50.93-14.43-32.58
Capital Expenditures
--0.04-0.89-5.41-6.14-1.15
Free Cash Flow
-26.43-48.02-29.83-56.34-20.57-33.73
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--88.78%-150.75%5.26%-
Operating Margin
---304.98%-10024.69%-6.43%-15380.60%
Pretax Margin
---409.03%-9541.40%1.90%-19082.09%
Profit Margin
---408.00%-9145.51%11.95%-18979.48%
FCF Margin
---199.29%-7024.69%-46.01%-12585.45%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----16.41-
PS Ratio
--3.25177.441.961445.93